DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20182386

Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection

Rawan Ageeli, Abdullah Binobaid, Abdullah Aljadaan, Mohammed Alhagbani, Yasser Alotaibi, Thamer Alenazi, Mohammed Alhajjaj, Abdullh Altawili, Fuad Alotaibi, Najlaa Felimban

Abstract


Background: Proton pump inhibitors (PPIs) are one of the most commonly used classes of drugs. Though, the quantum clinical benefit of newer and more expensive PPIs over the older generation PPIs residues undefined. The present meta-analysis ought to assess the safety and clinical profiles of esomeprazole versus omeprazole at pharmacologically equivalent doses in healing gastroesophageal reflux disease (GERD), peptic ulcer disease and eradicating Helicobacter pylori infection.

Methods: PubMed and the Cochrane Library were searched for randomized controlled trials comparing esomeprazole with omeprazole at all doses up to July 2017. Meta-analysis was conducted using a random effects model, and heterogeneity in the estimated effects was investigated using meta-regression.

Results: Eleven trials were included and none of which compared esomeprazole with omeprazole in peptic ulcer disease. In gastroesophageal reflux disease, esomeprazole 40 mg (relative risk (RR) = 1.11; 95% confidence interval (CI) 1.14 to 1.23) and 20 mg (RR=1.08; 95% CI 1.02 to 1.12) significantly improved esophagitis healing when compared with omeprazole 20 mg at week 8. In H. pylori eradication, there was no difference in the treatment effects between esomeprazole 20 mg and omeprazole 20 mg (RR = 1.05;95% CI 1.01 to 1.11).

Conclusions: Esomeprazole established better esophagitis healing rate in patients with GERD than omeprazole at week 8. Though, this clinical advantage reduced when both drugs were given at the same doses at week 4. Superiority of esomeprazole was not perceived in the H. pylori eradication rates.


Keywords


Proton pump inhibitors, Esomeprazole, Helicobacter pylori, Omeprazole

Full Text:

PDF

References


Peura DA, Berardi RR, Gonzalez J, Brunetti L. The value of branded proton pump inhibitors: formulary considerations. PT. 2011;36:434–45.

Omeprazole (Losec) Capsule Package Insert. Astra Zeneca August 2012. Available at: http://www.hsa.gov.sg

Saccar CL. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin Drug Metab Toxicol. 2009;5:1113–24.

Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther. 2001;15:1729–36.

Ip S, Chung M, Moorthy D, Yu WW, Lee J, Chan JA, et al. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease: Update. AHRQ Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality (US). 2011.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ. 2003;327:4.

Schmitt C, Lightdale CJ, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci. 2006;51:844–50.

Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World J Gastroenterol. 2009;15:990–5.

Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96:656–65.

Lightdale CJ, Schmitt C, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci. 2006;51:852–7.

Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther. 2000;14:1249–58.

Veldhuyzen Van Zanten S, Machado S, Lee J. One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;17:1381–7.

Subei IM, Cardona HJ, Bachelet E, Useche E, Arigbabu A, Hammour AA, et al. One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healing in Helicobacter pylori-positive patients. Dig Dis Sci. 2007;52:1505–12.

Sheu BS, Kao AW, Cheng HC, Hunag SF, Chen TW, Lu CC, et al. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther. 2005;21:283–8.

Choi HS, Park DI, Hwang SJ, Park JS, Kim HJ, Cho YK, et al. Doubledose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter. 2007;12:638-42.

Anagnostopoulos GK, Tsiakos S, Margantinis G, Kostopoulos P, Arvanitidis D. Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol. 2004;38:503–6.

Armstrong D, Talley NJ, Lauritsen K, Moum B, Lind T, Tunturi-Hihnala H, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004;20:413–21.

Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther. 2003;18:559–68.

Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007:CD003244.

Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther. 2006;24:743–50.

Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4:1452–8.